Study on the effect of disease modifiers on pain, fatigue and quality of life in patients with NMOSD

JRCT ID: jRCT1030210419

Registered date:10/11/2021

Basic Information

• Recruitment status: Pending
• Health condition(s) or Problem(s) studied: Neuromyelitis Optica Spectrum Disorders
• Date of first enrollment: 10/11/2021
• Target sample size: 30
• Study type: Observational

Outcome(s)

• Primary Outcome: Evaluation / measurement of motor function, ADL, disability, QOL, pain, fatigue, and depressive symptoms

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both
• Include criteria: The NMOSD diagnosis follows the diagnostic criteria of Wingerchuk et al. (Wingerchuk DM 2007, 2015). The subjects were patients who were diagnosed, treated, or newly diagnosed with neuromyelitis optica spectrum disorder (NMOSD) at our hospital from September 2020 to March 31, 2022. Patients who started administration of oral steroid humanized monoclonal antibody (Satralizumab, etc.) as a therapeutic intervention.
• Exclude criteria: Minors (under 20 years old)

Related Information

• Primary Sponsor: Kazuhiro Ishii